Literature DB >> 15516471

Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis.

C H Goss1, N Mayer-Hamblett, M L Aitken, G D Rubenfeld, B W Ramsey.   

Abstract

BACKGROUND: Stenotrophomonas maltophilia (SM) is a Gram-negative non-fermenting bacteria cultured from the sputum of patients with cystic fibrosis (CF). To date, no information is available regarding the effect of this organism on lung function in CF.
METHODS: A cohort study was conducted to assess the effect of SM on lung function among CF patients aged > or =6 years in the CF Foundation National Patient Registry from 1994 to 1999. Repeated measures regression was used to assess the association between SM and lung function.
RESULTS: The cohort consisted of 20 755 patients with median age at entry of 13.8 years and median follow up time of 3.8 years; 2739 patients (13%) were positive at least once for SM and 18 016 (87%) were never positive. After adjusting for sex, height and age, patients with SM had a mean forced expiratory volume in 1 second which was 0.09 l less (95% CI 0.05 to 0.14) than those without SM. The mean rate of decline associated with SM positivity was 0.025 l/year (95% CI 0.012 to 0.037) but, after adjusting for confounders (sex, height, weight, intravenous antibiotic courses, hospital admissions, pancreatic insufficiency, and Pseudomonas aeruginosa and Burkholderia cepacia status), the mean rate of decline decreased to 0.008 l/year (-0.008, 95% CI -0.019 to 0.003).
CONCLUSIONS: Although CF patients with SM have worse lung function at the time of positivity, no association was found between SM and increased rate of decline after controlling for confounders.

Entities:  

Mesh:

Year:  2004        PMID: 15516471      PMCID: PMC1746887          DOI: 10.1136/thx.2003.017707

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  16 in total

Review 1.  The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel.

Authors:  B J Rosenstein; G R Cutting
Journal:  J Pediatr       Date:  1998-04       Impact factor: 4.406

2.  Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients.

Authors:  M Denton; N J Todd; J M Littlewood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-05       Impact factor: 3.267

3.  Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis.

Authors:  J W Krzewinski; C D Nguyen; J M Foster; J L Burns
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

Review 4.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

5.  Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis.

Authors:  I Talmaciu; L Varlotta; J Mortensen; D V Schidlow
Journal:  Pediatr Pulmonol       Date:  2000-07

Review 6.  Pulmonary infections in patients with cystic fibrosis.

Authors:  Sujatha Rajan; Lisa Saiman
Journal:  Semin Respir Infect       Date:  2002-03

7.  Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis.

Authors:  M R Shreve; S Butler; H J Kaplowitz; H R Rabin; D Stokes; M Light; W E Regelmann
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

8.  Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence.

Authors:  C A Demko; R C Stern; C F Doershuk
Journal:  Pediatr Pulmonol       Date:  1998-05

9.  Microbiology of sputum from patients at cystic fibrosis centers in the United States.

Authors:  J L Burns; J Emerson; J R Stapp; D L Yim; J Krzewinski; L Louden; B W Ramsey; C R Clausen
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079

10.  Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis.

Authors:  Gavin R Graff; Jane L Burns
Journal:  Chest       Date:  2002-06       Impact factor: 9.410

View more
  44 in total

1.  Identification and management of unusual pathogens in cystic fibrosis.

Authors:  J Stuart Elborn
Journal:  J R Soc Med       Date:  2008-07       Impact factor: 5.344

2.  Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis.

Authors:  J Kirk Harris; Mary Ann De Groote; Scott D Sagel; Edith T Zemanick; Robert Kapsner; Churee Penvari; Heidi Kaess; Robin R Deterding; Frank J Accurso; Norman R Pace
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-11       Impact factor: 11.205

Review 3.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis.

Authors:  Clement L Ren; Michael W Konstan; Ashley Yegin; Lawrence Rasouliyan; Benjamin Trzaskoma; Wayne J Morgan; Warren Regelmann
Journal:  J Cyst Fibros       Date:  2012-03-23       Impact factor: 5.482

5.  Children and young adults with CF in the USA have better lung function compared with the UK.

Authors:  Christopher H Goss; Stephanie J MacNeill; Hebe B Quinton; Bruce C Marshall; Alexander Elbert; Emily A Knapp; Kristofer Petren; Elaine Gunn; Joanne Osmond; Diana Bilton
Journal:  Thorax       Date:  2014-09-25       Impact factor: 9.139

Review 6.  Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Authors:  Reshma Amin; Valerie Waters
Journal:  Cochrane Database Syst Rev       Date:  2016-07-14

7.  Stenotrophomonas maltophilia Differential Gene Expression in Synthetic Cystic Fibrosis Sputum Reveals Shared and Cystic Fibrosis Strain-Specific Responses to the Sputum Environment.

Authors:  Graham G Willsey; Korin Eckstrom; Annette E LaBauve; Lauren A Hinkel; Kristin Schutz; Robert J Meagher; John J LiPuma; Matthew J Wargo
Journal:  J Bacteriol       Date:  2019-07-10       Impact factor: 3.490

Review 8.  Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Authors:  Edith T Zemanick; J Kirk Harris; Steven Conway; Michael W Konstan; Bruce Marshall; Alexandra L Quittner; George Retsch-Bogart; Lisa Saiman; Frank J Accurso
Journal:  J Cyst Fibros       Date:  2009-10-14       Impact factor: 5.482

9.  Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients.

Authors:  Arianna Pompilio; Valentina Crocetta; Pamela Confalone; Mauro Nicoletti; Andrea Petrucca; Simone Guarnieri; Ersilia Fiscarelli; Vincenzo Savini; Raffaele Piccolomini; Giovanni Di Bonaventura
Journal:  BMC Microbiol       Date:  2010-04-07       Impact factor: 3.605

10.  Recurrent hemoptysis with Penicillium marneffei and Stenotrophomonas maltophilia in Job's syndrome.

Authors:  Bosco H M Ma; Calvin S H Ng; Rebecca K Y Lam; Song Wan; Innes Y P Wan; Tak Wai Lee; Anthony P C Yim
Journal:  Can Respir J       Date:  2009 Jul-Aug       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.